Bristol Myers Squibb drug Augtyro now has a tumor-agnostic approval permitting the drug to be used to treat all solid tumors positive for NTRK gene fusions. Augtyro came from BMS’s $4.1 billion acquisition of Turning Point Therapeutics.
The post New FDA Nod Brings Bristol Myers Squibb Cancer Drug to a Wider Range of Solid Tumors appeared first on MedCity News.
Related Articles
A Baby Step Backwards
Bringing the Tools of Accountable Care to Maternity Care is a Great...
What share of physicians are integrated within hospital systems?
This questions may be harder to answer than it may seem. While...
Two Venture Investors Offer Their Takes on the State of Biotech Investing Today
The way venture capital firms invest in biotech startups has changed. Veteran...
Houston Stevens – Bringing a Culture of Service Excellence to EVS
Working at the Four Seasons hotel in Washington, D.C., Houston Stevens provided...
Leave a comment